Laddar populära aktier...
Redeye comments on Sivers’ announcement of a new CEO, which Redeye believes to be a good fit for the...
Consti’s Q2 results beat our estimates for both net sales and EBIT.
- 25% miss on adj EBIT - Lower on sales and weaker gross margin - Estimates likely down 5-8% on adj.
- We cut '24e sales and EBITDA by 2% and 21%, respectively - Headwinds for Aurdel likely to persist ...
Vitrolife delivered a surprising organic growth recovery with 4% organic growth and even if there wa...
Redeye thinks the Q2 report was strong in all aspects.
Redeye states that with improved growth rates for recurring revenues, Truecaller is quickly becoming...
- Sales decline 6% y-o-y as EBIT remains at break-even - Weak restaurant and hotel market hamper NW&...
Incap upgraded its 2024 full-year guidance on 18 July.
- Q2'24 results due 20 August - 142% growth y-o-y for Catalyst, +9.
Redeye sustains its positive view of CombinedX despite a weak Q2 report, with margins substantially ...
- Q2 deliveries impressed, less support ahead but still good demand - 2024e adj.
- Sales +1% vs. ABGSCe (-5% y-o-y), EBIT +4% vs. ABGSCe - Ework continues to see recovery in demand ...
- Strong growth, adj. EBIT +14% vs cons but orders -8% vs cons - Activity level to remain high for m...
Redeye comments on Invisio’s Q2-results which came in above expectations owing to strong deliveries ...
